What does CUSIP 008064206 represent in this 13F holders report?

CUSIP 008064206 is the security identifier for JBIO - Jade Biosciences, Inc. - Common Stock used to aggregate holder disclosures.

How many institutions held JBIO - Jade Biosciences, Inc. - Common Stock in Q3 2025?

74 institutional investors reported JBIO - Jade Biosciences, Inc. - Common Stock for Q3 2025. Use the holders table for investor-level position and value details.

Jade Biosciences, Inc. - Common Stock (JBIO)

CUSIP: 008064206

Q3 2025 13F Holders as of 30 Sep 2025

Type / Class: Equity / Common Stock
Shares outstanding: 49,296,333
Total 13F shares: 31,617,300
Share change: +74,107
Total reported value: $272,859,518
Price per share: $8.63
Number of holders: 74
Value change: +$407,366
Number of buys: 29
Number of sells: 26

Quarterly Holders Quick Answers

What is CUSIP 008064206?
CUSIP 008064206 identifies JBIO - Jade Biosciences, Inc. - Common Stock in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q4 2025
Previous quarter: Q2 2025

Recent filing periods for CUSIP 008064206:

Q1 2026 Q4 2025 Q3 2025 Q2 2025

Top shareholders of JBIO - Jade Biosciences, Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Sofinnova Venture Partners X, L.P.	3/4/5 13D/G	10%+ Owner · Sofinnova Venture Partners X, L.P. ("SVP X")	0.3% from 13D/G	3,758,686	$73,294,377	—	02 Jul 2021	3/4/5 13D/G
David S. Grayzel	3/4/5	Director	— mixed-class rows	1,811,732 mixed-class rows	$50,853,006	—	05 Jun 2024	3/4/5
FMR LLC	13F 13D/G	Company	15% from 13D/G	4,835,383	$48,305,476	—	30 Jun 2025	13F 13D/G
Atlas Venture Fund XII, L.P.	3/4/5 13D/G	10%+ Owner · Atlas Venture Associates XII, L.P.	0.2% from 13D/G	2,327,909	$45,394,226	—	15 Jul 2022	3/4/5 13D/G
Cormorant Asset Management, LP	3/4/5	Former 10% Owner	— class O/S missing	2,030,691	$39,598,475	—	02 Jul 2021	3/4/5
Fairmount Funds Management LLC	13F	Company	6.5%	3,220,368	$32,171,476	—	30 Jun 2025	13F
VR Adviser, LLC	13F	Company	6.5%	3,220,364	$32,171,436	—	30 Jun 2025	13F
Deep Track Capital, LP	13F	Company	5.1%	2,509,301	$25,067,917	—	30 Jun 2025	13F
VANGUARD GROUP INC	13F	Company	3.7%	1,807,582	$18,057,744	—	30 Jun 2025	13F
Frazier Life Sciences Management, L.P.	13F	Company	3.6%	1,772,116	$17,703,439	—	30 Jun 2025	13F
BlackRock, Inc.	13F	Company	3.5%	1,714,348	$17,126,337	—	30 Jun 2025	13F
Versant Venture Management, LLC	13F	Company	3.1%	1,525,820	$15,242,942	—	30 Jun 2025	13F
RTW INVESTMENTS, LP	13F	Company	2.9%	1,449,273	$14,478,237	—	30 Jun 2025	13F
DRIEHAUS CAPITAL MANAGEMENT LLC	13F	Company	2.5%	1,255,798	$12,545,422	—	30 Jun 2025	13F
Frazier Life Sciences Public Fund, L.P.	13D/G	—	4.2%	1,384,646	$11,949,495	+$379,228	30 Sep 2025	13D/G
Avidity Partners Management LP	13F	Company	2.3%	1,127,186	$11,260,588	—	30 Jun 2025	13F
RA CAPITAL MANAGEMENT, L.P.	13F 3/4/5	Company · 10%+ Owner	2.2%	1,062,326	$10,612,637	—	30 Jun 2025	13F 3/4/5
Soleus Capital Management, L.P.	13F	Company	1.6%	796,744	$7,959,473	—	30 Jun 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	1.4%	676,431	$6,758,954	—	30 Jun 2025	13F
Logos Global Management LP	13F	Company	1.3%	625,000	$6,243,750	—	30 Jun 2025	13F
Timothy P. Noyes	3/4/5	CHIEF EXECUTIVE OFFICER, Director	— class O/S missing	343,381	$5,621,147	—	16 May 2024	3/4/5
DEERFIELD MANAGEMENT COMPANY, L.P.	13F	Company	1.1%	531,163	$5,306,318	—	30 Jun 2025	13F
ORBIMED ADVISORS LLC	13F	Company	1.1%	531,163	$5,306,318	—	30 Jun 2025	13F
Samsara BioCapital, LLC	13F	Company	1.1%	531,163	$5,306,318	—	30 Jun 2025	13F
GREAT POINT PARTNERS LLC	13F	Company	1%	498,054	$4,975,559	—	30 Jun 2025	13F
STATE STREET CORP	13F	Company	0.65%	318,771	$3,184,522	—	30 Jun 2025	13F
BARCLAYS PLC	13F	Company	0.56%	274,830	$2,745,552	—	30 Jun 2025	13F
NORTHERN TRUST CORP	13F	Company	0.46%	228,092	$2,278,638	—	30 Jun 2025	13F
Hunter Gillies	3/4/5	CHIEF MEDICAL OFFICER	— mixed-class rows	89,112 mixed-class rows	$1,504,308	—	13 Jun 2024	3/4/5
Marinus Verwijs	3/4/5	CHIEF TECHNICAL OFFICER	— class O/S missing	68,800	$1,126,256	—	14 Jun 2024	3/4/5
Sofinnova Investments, Inc.	13F	Company	0.22%	107,391	$1,072,836	—	30 Jun 2025	13F
Woodline Partners LP	13F	Company	0.22%	106,270	$1,061,637	—	30 Jun 2025	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.21%	103,255	$1,031,517	—	30 Jun 2025	13F
Timothy Pigot	3/4/5	CHIEF COMMERCIAL OFFICER	— mixed-class rows	67,877 mixed-class rows	$923,420	—	22 Jan 2024	3/4/5
Bank of New York Mellon Corp	13F	Company	0.16%	78,393	$783,146	—	30 Jun 2025	13F
Affinity Asset Advisors, LLC	13F	Company	0.13%	65,317	$652,517	—	30 Jun 2025	13F
TCG Crossover GP I, LLC	13D/G	—	0.2%	64,023	$649,193	$0	28 Apr 2025	13D/G
TCG Crossover Management, LLC	13F	Company	0.13%	64,023	$639,590	—	30 Jun 2025	13F
Nuveen, LLC	13F	Company	0.12%	60,128	$600,679	—	30 Jun 2025	13F
George A. Eldridge	3/4/5	Officer Title: Chief Financial Officer and Treasurer	— mixed-class rows	33,785 mixed-class rows	$596,551	—	14 Jun 2024	3/4/5
Ralph Niven	3/4/5	CHIEF SCIENTIFIC OFFICER	— mixed-class rows	43,341 mixed-class rows	$591,035	—	05 Feb 2024	3/4/5
MORGAN STANLEY	13F	Company	0.1%	49,773	$497,231	—	30 Jun 2025	13F
RHUMBLINE ADVISERS	13F	Company	0.09%	44,570	$445,243	—	30 Jun 2025	13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP	13F	Company	0.08%	39,229	$391,898	—	30 Jun 2025	13F
XTX Topco Ltd	13F	Company	0.05%	25,752	$257,262	—	30 Jun 2025	13F
DEUTSCHE BANK AG\	13F	Company	0.05%	25,614	$255,884	—	30 Jun 2025	13F
INTECH INVESTMENT MANAGEMENT LLC	13F	Company	0.05%	22,995	$229,720	—	30 Jun 2025	13F
Lawrence Otto Klein	3/4/5	Director	— mixed-class rows	109,232 mixed-class rows	$229,331	—	29 Apr 2025	3/4/5
Quantinno Capital Management LP	13F	Company	0.04%	21,986	$219,640	—	30 Jun 2025	13F
UBS Group AG	13F	Company	0.04%	21,038	$210,170	—	30 Jun 2025	13F

Institutional Holders of Jade Biosciences, Inc. - Common Stock (JBIO) as of Q3 2025

As of 30 Sep 2025, Jade Biosciences, Inc. - Common Stock (JBIO) was held by 74 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 31,617,300 shares. The largest 10 holders included FMR LLC, Fairmount Funds Management LLC, VR ADVISER, LLC, Deep Track Capital, LP, BlackRock, Inc., VANGUARD GROUP INC, Versant Venture Management, LLC, RTW INVESTMENTS, LP, Frazier Life Sciences Management, L.P., and Driehaus Capital Management LLC. This page lists 74 institutional shareholders reporting positions in this security for the Q3 2025 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q3 2025 vs Q2 2025 Across Filers

Q2 2025 holders

Q3 2025 holders

Holder diff

Investor	Q2 2025 Shares	Q3 2025 Shares	Share Diff	Share Chg %	Q2 2025 Value $	Q3 2025 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.